Format

Send to

Choose Destination
J Bone Jt Infect. 2018 Nov 24;3(5):255-257. doi: 10.7150/jbji.30029. eCollection 2018.

Rifampin-Resistant Cutibacterium (formerly Propionibacterium) namnetense Superinfection after Staphylococcus aureus Bone Infection Treatment.

Author information

1
Service de Bactériologie-Hygiène hospitalière, CHU de Nantes, Nantes, France.
2
CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.
3
Nantes study group member of CRIOGO (Centre de Référence des Infections Ostéo-articulaires du Grand Ouest), Nantes, France.
4
Clinique chirurgicale orthopédique et traumatique, CHU de Nantes, Nantes, France.
5
Service de Maladies infectieuses, CHU de Nantes, Nantes, France - Département de Médecine Interne -Infectiologie, Nouvelles Cliniques Nantaises, Nantes, France.

Abstract

After rifampin and levofloxacin treatment for a Staphylococcus aureus bone infection, a pyogenic granuloma due to a newly described Cutibacterium species, C. namnetense developed on the tibia former external fixator. This rifampin resistant bacterium, selected during treatment, harbored a mutation in the rpoB gene. This case illustrates the possible in vivo selection of resistant mutant most likely due to the bacterial burden and therefore the importance of adequate bone infection treatment.

KEYWORDS:

Staphylococcus aureus; Cutibacterium namnetense; bone infection; resistance; rifampin

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Supplemental Content

Full text links

Icon for Ivyspring International Publisher Icon for PubMed Central
Loading ...
Support Center